AI eye test could save your sight: 4,300-Patient trial launches
NCT ID NCT07069647
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests whether an AI tool (VeriSee) can help doctors detect two common causes of vision loss—diabetic retinopathy and age-related macular degeneration—earlier than standard exams. About 4,300 adults with diabetes or aged 50+ will be randomly assigned to AI-assisted screening or usual care. The goal is to see if AI improves detection rates and leads to timely treatment, potentially preventing severe vision loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, 100225, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tight blood sugar control protect the eyes? a study uses advanced imaging to find out
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study